Infinity Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Infinity Pharmaceuticals generated cash of -$42,431,000, which is less than the previous year. Cash used in financing activities reached the amount of $73,000 last year. Net change in cash is therefore -$42,413,000.
Cash Flow
| 2019 | -41.53M | -12.24M | 27.73M |
|---|---|---|---|
| 2022 | -42.43M | -55K | 73K |
INFIQ Cash Flow Statement (2019 – 2022)
| 2022 | 2019 | |
|---|---|---|
Cash at beginning of period | 80.88M | 48.61M |
Operating activities | ||
Net income | -44.36M | -47.05M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 458K | 219K |
Stock-based compensation expense | 3.62M | 2.13M |
| Deferred income tax benefit | 3.62M | 2.13M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | -300K | 1.55M |
Cash generated by operating activities | -42.43M | -41.53M |
Investing activities | ||
Purchases Of Investments | -16.03M | -41.86M |
Investments In Property Plant And Equipment | -17K | -2.32M |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -55K | -12.24M |
Financing activities | ||
Common Stock Issued | 73K | 112K |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | 0 |
Cash used in financing activities | 73K | 27.73M |
Net Change In Cash | -42.41M | -26.04M |
Cash at end of period | 38.47M | 22.57M |